

Follow the Patents... ...It will take you to the money

Dr. David E. Martin

www.davidmartin.world





This MANDATORY INJECTION was planned in 2015 by the COVID RICO CONSPIRATORS

“...until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process, Daszak stated.”

2016 Feb 12. 6, *Developing MCMs for Coronaviruses*. Available from:
<https://www.ncbi.nlm.nih.gov/books/NBK349040/>



In recognition of these limitations, the President signed the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health on **September 19, 2019**. Broadly, the Executive Order directs BARDA, CDC, NIH, and FDA to accelerate the adoption of improved influenza vaccine technologies. In alignment with the goals of the Executive Order, NIAID is conducting and supporting research to develop state-of-the-art vaccine platform technologies that could be used to develop universal influenza vaccines as well as to improve the speed and agility of the influenza vaccine manufacturing process. **These platform technologies include DNA, messenger RNA (mRNA), virus-like particles, vector-based, and self-assembling nanoparticle vaccines.** For example, NIAID supported scientists are investigating an mRNA vaccine candidate that would allow for a more rapid and flexible response to both seasonal and pandemic influenza than do existing vaccine production strategies.

<https://energycommerce.house.gov/sites/democrats.energycommerce.house.gov/files/documents/Testimony%20-%20Fauci%20%28NIH%29%2012.04.2019.pdf>

The COVID World at VAX




1473-1474 (2020) 1473-1474
 (43) Date de la publication internationale
 20 février 2020 (2020:2002)
 (44) Classification internationale des brevets
 A61K 39/12 (2006)
 (45) Numéro de la demande internationale
 PCT/US2019/021211
 (46) Date de dépôt international
 9 août 2019 (2019:0809)
 (47) Langue de dépôt
 Anglais
 (48) Langue de publication
 Anglais
 (49) Numéro assigné à la priorité
 15/100000
 (50) Inventeurs
 (51) Inventeur principal
 (52) Inventeurs secondaires
 (53) Inventeurs tiers
 (54) Inventeurs quaternaires
 (55) Inventeurs quinquaires
 (56) Inventeurs sexaires
 (57) Inventeurs septaires
 (58) Inventeurs octaires
 (59) Inventeurs non classés
 (60) Demandes antérieures
 (61) Demandes étrangères
 (62) Demandes nationales
 (63) Demandes étrangères
 (64) Demandes étrangères
 (65) Demandes étrangères
 (66) Demandes étrangères
 (67) Demandes étrangères
 (68) Demandes étrangères
 (69) Demandes étrangères
 (70) Demandes étrangères
 (71) Demandes étrangères
 (72) Demandes étrangères
 (73) Demandes étrangères
 (74) Demandes étrangères
 (75) Demandes étrangères
 (76) Demandes étrangères
 (77) Demandes étrangères
 (78) Demandes étrangères
 (79) Demandes étrangères
 (80) Demandes étrangères
 (81) Demandes étrangères
 (82) Demandes étrangères
 (83) Demandes étrangères
 (84) Demandes étrangères
 (85) Demandes étrangères
 (86) Demandes étrangères
 (87) Demandes étrangères
 (88) Demandes étrangères
 (89) Demandes étrangères
 (90) Demandes étrangères
 (91) Demandes étrangères
 (92) Demandes étrangères
 (93) Demandes étrangères
 (94) Demandes étrangères
 (95) Demandes étrangères
 (96) Demandes étrangères
 (97) Demandes étrangères
 (98) Demandes étrangères
 (99) Demandes étrangères
 (100) Demandes étrangères



Countries, donors and multilateral institutions must be prepared for the worst.

A rapidly spreading pandemic due to a lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any new pathogen for public health purposes along with the means to share limited medical countermeasures across countries.

Progress indicator(s) by September 2020
 • Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad spectrum antiviral, and targeted therapeutics. WHO and its Member States develop options for standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.



United States Patent [14] [31] Patent Number: 4,904,468
 Gill et al. [45] Date of Patent: Feb. 27, 1990

[34] CANINE CORONAVIRUS VACCINE
 [75] Inventors: Michael A. Gill, Stephen W. May, both of Lincoln, Neb.
 [76] Assignor: Norton Laboratories, Inc., Lincoln, Neb.
 [21] Appl. No.: 99,437
 [22] Filed: Jun. 9, 1987
 [31] Int. Cl. A61K 39/12, C12N 7/00
 [32] U.S. Cl. 424/99, 435/215
 [33] 435/236, 435/237, 435/238, 435/239
 [34] Field of Search: 424/99, 435/215-239

REFERENCE CITED
 4,287,242 V1986 Anne et al. 424/99
 4,352,042 V1986 Anne et al. 424/99

FOREIGN PATENT DOCUMENTS
 WO/00/0614 V1998 PCT Int. Appl. - WO/00/0614 V1998 PCT Int. Appl. -
 OTHER PUBLICATIONS
 Skidell et al., "The Structure and Replication of Corona

[37] ABSTRACT
 A vaccine for protecting canine animals from disease caused by infection with canine coronavirus (CCV) which comprises an effective amount of the said associated CCV polypeptide protein. A polyvalent vaccine comprising an effective amount of self-associated CCV polypeptide protein and an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms of V1986 are also disclosed.

13 Claims, No Drawings

Zoonotic anticipation and preparedness initiative (ZAPI)

2015-03 to 2020-03 | Grant
 Innovative Medicines Initiative Joint Undertaking (IMI JU), European Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies (Brussels, Belgium)
 GRANT_NUMBER: 115760

Organization identifiers
 FUNDREF: <https://doi.org/10.13039/501100000739>
 European Commission:

Total funding amount
 EUR 22,360,163

Added
 2020-03-07

Last modified
 2020-07-04

Source: Bart Haeghebaert

(12) International Publication Number
 PCT/US2019/021211
 (43) International Publication Date
 21 October 2020 (2020:1021)
 (44) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(51) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(52) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(53) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(54) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(55) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(56) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(57) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(58) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(59) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(60) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(61) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(62) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(63) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(64) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(65) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(66) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(67) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(68) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(69) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(70) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(71) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(72) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(73) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(74) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(75) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(76) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(77) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(78) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(79) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(80) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(81) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(82) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(83) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(84) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(85) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(86) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(87) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(88) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(89) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(90) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(91) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(92) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(93) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(94) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(95) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00


(96) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(97) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(98) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(99) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00

(100) International Patent Classification
 CPTA F48M
 C12N 1/00, A61K 39/12, C12Q 1/00, G01N 33/00, A61K 39/12, G01N 33/00



Dr. Seth Berkley
 Chief Executive Officer
 GAVI Alliance

Dr. Margaret Chan
 Director General
 World Health Organization

Dr. Christopher Elias
 President
 Global Development Program
 Bill & Melinda Gates Foundation

Dr. Christopher Elias
 President
 Global Development Program
 Bill & Melinda Gates Foundation

Mr. Anthony Lake
 Executive Director
 United Nations Children's Fund (UNICEF)

Ms. Joy Phumaphi
 Executive Secretary
 African Leaders Malaria Alliance

Dr Chris Elias
 President, Global Development Program, Bill & Melinda Gates Foundation, USA

Dr Anthony S. Fauci
 Director, National Institute of Allergy and Infectious Diseases, USA

Dr George F. Gao
 Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China

The COVID Privateers



- Operation Warp Speed
 - armaments, biotechnology, electromagnetic spectrum, space technologies, advanced materials, shipbuilding



- Vaccine Marketing



- Gotham Data Tracking



- HHS IT

- Pfizer

- Moderna

- Johnson&Johnson

- Merck Ridgeback

- Gilead Sciences



IMPLEMENTING
COUNTRY
OPERATIONS


DONOR
COUNTRY
OPERATIONS

CIVIL SOCIETY
ORGANISATIONS

RESEARCH
OPERATIONS

VACCINE
MANUFACTURERS

PRIVATE SECTOR
OPERATIONS



The COVID Pirates



- UNC Chapel Hill
 - Ralph Baric's Chimera Lab



VANDERBILT
UNIVERSITY

- Vanderbilt



EMORY
UNIVERSITY

- Emory



JOHNS HOPKINS
UNIVERSITY

- Johns Hopkins



- University of California System

- MIT



- NYU Langone



- DZIF
 - Prof. Dr. Christian Drosten



- Imperial College



- IHME



- Erasmus MC
 - Dr. B.L. Haagmans



The COVID Orchestra

Board of Trustees



Mukesh D. Ambani
Chairman and Managing Director, Reliance Industries



Peter Brabeck-Letmathe
Vice-Chairman of the Board of Trustees, World Economic Forum



Mark Carney
United Nations Special Envoy for Climate Action and Finance, United Nations



Chrystia Freeland
Deputy Prime Minister and Minister of Finance, Office of the Deputy Prime Minister of Canada



Kristalina Georgieva
Managing Director, International Monetary Fund (IMF)



H.M. Queen Rania Al Abdullah of the Hashemite Kingdom of Jordan
Queen of the Hashemite Kingdom of Jordan, Office of Her Majesty Queen Rania Al Abdullah



David M. Rubenstein
Co-Founder and Co-Executive Chairman, Carlyle Group



Klaus Schwab
Founder and Executive Chairman, World Economic Forum



Marc Benioff
Chair and Chief Executive Officer, Salesforce



Thomas Buberl
Chief Executive Officer, AXA



Laurence D. Fink
Chairman and Chief Executive Officer, BlackRock



Orit Gadiesh
Chairman, Bain & Company



Fabiola Gianotti
Director-General, European Organization for Nuclear Research (CERN)



L. Rafael Reif
President, Massachusetts Institute of Technology



Mark Schneider
Chief Executive Officer, Nestlé



Tharman Shanmugaratnam
Senior Minister, Government of Singapore



Robert Mercer
Renaissance Fund



Larry Page
Google



Al Gore
Vice-President of the United States (1993-2001); Chairman and Co-Founder, Generation Investment Management LLP



Angel Gurría
OECD



Paula Ingabire
Minister of Information Communication Technology and Innovation, Ministry of Information Communication Technology and Innovation of Rwanda



Yo-Yo Ma
Cellist,



Luis Alberto Moreno
Member of the Board of Trustees, World Economic Forum



Jim Hagemann Snape
Chairman, Siemens



Feike Sybesma
Chairman of the Supervisory Board, Royal Philips



Zhu Min
Chairman, National Institute of Financial Research



Mark Zuckerberg
Facebook



Bill Gates
Bill & Melinda Gates Foundation



Herman Gref
Chief Executive Officer and Chairman of the Board, Sberbank



André Hoffmann
Vice-Chairman, Roche



Christine Lagarde
President, European Central Bank



Peter Maurer
President, International Committee of the Red Cross (ICRC)



Patrice Motsepe
Founder and Executive Chairman, African Rainbow Minerals



Julie Sweet
Chief Executive Officer, Accenture



Heizo Takenaka
Professor Emeritus, Keio University



Dustin Moskovitz
Open Philanthropy

The COVID Conspiring States



The COVID Treasonous Acts

CRIMINAL

- 18 U.S.C. §2339 C *et seq.* – funding and conspiring acts of terror
- 18 U.S.C. § 2331 §§ 802 – acts of domestic terrorism resulting in death of American Citizens
- 18 U.S.C. § 1001 – lying to Congress
- 15 U.S.C. §1-3 – conspiring to criminal commercial activity
- 15 U.S.C. §8 – market manipulation and allocation
- 15 U.S.C. § 19 – interlocking directorates

CIVIL

- 35 U.S.C. §206 – disclosure of government interest
- 35 U.S.C. §101 – patenting nature
- 21 C.F.R. § 50.24 *et seq.*, it is unlawful to conduct medical research (even in the case of emergency) without an independent institutional review board approved protocol including informed consent free of coercion.
- 15 U.S.C. §45 §§5(a) “unfair or deceptive acts or practices in or affecting commerce.”



Emergency does not create power. Emergency does not increase granted power or remove or diminish the restrictions imposed upon power granted or reserved. The Constitution was adopted in a period of grave emergency. Its grants of power to the Federal Government and its limitations of the power of the States were determined in the light of emergency, **and they are not altered by emergency.** What power was thus granted and what limitations were thus imposed are questions which have always been, and always will be, the subject of close examination under our constitutional system. While emergency does not create power, emergency may furnish the occasion for the exercise of power.

Home Building & Loan Ass'n v. Blaisdell, 290 U.S. 398, 425-426 (1934).

The COVID “Intolerable Acts”

- Amendment I

- Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the people peaceably to assemble, and to petition the Government for a redress of grievances.

While Congress didn't restrict speech, assembly, or right to petition, it made no effort to uphold and defend these rights. Further, it stood by as these rights were abused by every Emergency Declaration in violation of Supreme Court rulings. By allowing Federal Contractors to disregard the Constitution, they've violated this Amendment.

The COVID “Intolerable Acts”

- Amendment IV

- The right of the people to be secure in their persons, houses, papers, and effects, against unreasonable searches and seizures, shall not be violated, and no Warrants shall issue, but upon probable cause, supported by Oath or affirmation, and particularly describing the place to be searched, and the persons or things to be seized.

By declaring every person a probable “asymptomatic carrier” the Federal Government (CDC, FDA, and DHHS) violated this Amendment and enabled the reckless abuse that harmed countless individuals. Loss of life, liberty and livelihood has been a DIRECT result.

The COVID “Intolerable Acts”

- Amendment V
 - nor shall be compelled in any criminal case to be a witness against himself, nor be deprived of life, liberty, or property, without due process of law; nor shall private property be taken for public use, without just compensation.

There has been no due process as the Courts have unilaterally stipulated the “epidemic” or “pandemic” without a single effort to demonstrate, beyond reasonable doubt, that there is either. Further, while changing the definition of “vaccine” to include “gene therapy”, the courts have inappropriately applied *Jacobson*

The COVID “Intolerable Acts”

- Amendment VI

- In all criminal prosecutions, the accused shall enjoy the right to a speedy and public trial, by an impartial jury of the State and district wherein the crime shall have been committed, which district shall have been previously ascertained by law, and to be informed of the nature and cause of the accusation; to be confronted with the witnesses against him; to have compulsory process for obtaining witnesses in his favor, and to have the Assistance of Counsel for his defence.

No judicial standard has been applied to validate the false claims of SARS CoV-2 “causing” COVID-19. Therefore, every derivative prosecution is in violation of the Sixth Amendment. No court has been willing to sit and consider the voluminous evidence of anti-trust, coercion and domestic terrorism, and racketeering charges against FDA, CDC, NIAID, Moderna, Pfizer, Johnson&Johnson, and their accomplices

The COVID “Intolerable Acts”

- Amendment X
 - The powers not delegated to the United States by the Constitution, nor prohibited by it to the States, are reserved to the States respectively, or to the people.

The final clause in the Tenth Amendment “or to the people” has been supplanted by States assuming police powers without limit. This tyranny effectively nullifies all Constitutional protections.




Magna Carta – 1215

- Right to due process, consent, and protection from deprivations of life, liberty, and livelihood
- Served as the basis for the Fifth Amendment to the U.S. Constitution
 - No person shall be held to answer for a capital, or otherwise infamous crime, unless on a presentment or indictment of a Grand Jury, except in cases arising in the land or naval forces, or in the Militia, when in actual service in time of War or public danger; nor shall any person be subject for the same offence to be twice put in jeopardy of life or limb; *nor shall be compelled in any criminal case to be a witness against himself, nor be deprived of life, liberty, or property, without due process of law*; nor shall private property be taken for public use, without just compensation.



The Charter of the Forest - 1217

- Recognized the rights of people to have:
 - Due process (Ch. 8)
 - Liberty of movement (Ch. 9)
 - Liberty of shelter (Ch. 2)
 - Liberty of livelihood & commerce (Ch. 12)
- Amended in 1225 to include a 15% flat tax



Virginia Declaration of Rights - 1776

- "That all Men are born equally free and independant, and have certain inherent natural Rights, of which they can not by any Compact, deprive or divest their Posterity; among which are the Enjoyment of Life and Liberty, with the Means of acquiring and possessing Property, and pursueing and obtaining Happiness and Safety."

The Integral Cure... *what "We The People" Means*

Our Inalienable Condition

By nature, provisioned for life, liberty and livelihood
unrestricted from provisioning

At liberty to peacefully assemble, speak, disagree, express,
believe, choose

Freedom of Inquiry with assurance of veracity and provenance

At liberty to exchange value and commerce with transparency

Afforded access to all derivatives of public goods

Organically undefiled from birth to death



The Continental Conventions Begin...

